Waldo Ortuzar

Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panel

Olivier Rixe, Waldo Ortuzar, Manuel Álvarez et al. · Biochemical Pharmacology · 1996 · 612 citations

National Cancer Institute, Medicine, Pharmacology +7

PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer

Ralph Zinner, Coleman K. Obasaju, David R. Spigel et al. · Journal of Thoracic Oncology · 2014 · 171 citations · Full text

Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations

Tito Fojo, Nick Farrell, Waldo Ortuzar et al. · Critical Reviews in Oncology/Hematology · 2004 · 53 citations

Oncology, Novel Cytotoxicity Profiles, Medicine +9

Association of common ATMvariants with familial breast cancer in a South American population

Patricio González‐Hormazábal, Teresa Bravo, Rafael Blanco et al. · BMC Cancer · 2008 · 36 citations · Full text

Brain Metastases as the Primary Site of Relapse in Two Randomized Phase III Pemetrexed Trials in Advanced Non–Small-Cell Lung Cancer

Waldo Ortuzar, Nasser H. Hanna, Eduardo J. Pennella et al. · Clinical Lung Cancer · 2011 · 30 citations

Primary Site, Neuro-oncology, Brain Metastases +9